Compare RTX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | NVO |
|---|---|---|
| Founded | 1934 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.3B | 269.6B |
| IPO Year | N/A | N/A |
| Metric | RTX | NVO |
|---|---|---|
| Price | $198.77 | $49.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 10 |
| Target Price | ★ $190.69 | $54.25 |
| AVG Volume (30 Days) | 6.4M | ★ 26.4M |
| Earning Date | 01-27-2026 | 02-04-2026 |
| Dividend Yield | 1.36% | ★ 2.48% |
| EPS Growth | ★ 39.72 | 1.77 |
| EPS | ★ 4.96 | 3.62 |
| Revenue | ★ $88,603,000,000.00 | $48,588,245,669.00 |
| Revenue This Year | $6.40 | $1.02 |
| Revenue Next Year | $6.66 | $6.81 |
| P/E Ratio | $40.33 | ★ $13.61 |
| Revenue Growth | ★ 9.74 | 6.43 |
| 52 Week Low | $112.27 | $43.08 |
| 52 Week High | $206.48 | $93.80 |
| Indicator | RTX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 41.90 |
| Support Level | $193.08 | $48.08 |
| Resistance Level | $200.85 | $50.07 |
| Average True Range (ATR) | 5.08 | 2.07 |
| MACD | -0.45 | -0.98 |
| Stochastic Oscillator | 68.81 | 31.96 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.